Ascendis Pharma Q4 2023 GAAP EPS $(1.66) Misses $(1.59) Estimate, Sales $148.22M Up From $23.37M YoY
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma (NASDAQ:ASND) reported a Q4 2023 GAAP EPS of $(1.66), missing the $(1.59) estimate, with sales reaching $148.22M, a 534.24% increase from $23.37M YoY.

February 07, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendis Pharma reported a Q4 2023 GAAP EPS of $(1.66), missing estimates, but showed significant sales growth to $148.22M, a 534.24% increase YoY.
While the EPS miss might concern some investors, the substantial increase in sales indicates strong revenue growth, which could offset concerns about profitability in the short term. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100